Unknown Brain & Nervous System NIHR-supported project Digestion, Kidneys & Other Organs
A randomized, double-blinded, placebo-controlled, Phase 2, parallel-group study to evaluate the efficacy, safety, tolerability, pharmacodynamics, pharmacokinetics, and immunogenicity of efgartigimod PH20 SC administered by prefilled syringe in Adult participants with Systemic Sclerosis
About this grant
This summary is based on the grant title only — the full abstract was not available.
No substantive source abstract was published for this research project funded by NIHR.
Researchers
Voon Ong (Principal Investigator)
Related Research
Grants with similar aims, by meaning.
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy
A phase III, randomized, double-blinded, placebo-controlled multicenter trial to evaluate the efficacy, safety and tolerability of efgartigimod PH20 SC administered by prefilled syringe (PFS) in adult patients with primary Sjogren’s syndrome (pSS)
A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients with Chronic Inflammatory DemyeliN/Ating Polyneuropathy (CIDP). (ADHERE)
A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). (ADHERE)
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research. Is something wrong? Let us know